Work

Supplementary Figures S1 - S2 from Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure S1. (A) Patient plasma fulvestrant levels at day 28 and 84 as measured by LC/MS/MS. (B) Patient serum estradiol (E2) levels at baseline, day 28 and 84, measured by fluorescent-immuno-assay and corrected for fulvestrant cross-reactivity. Supplemental Figure S2. Cross-reactivity between fulvestrant and estradiol (E2) fluorescent-immuno-assay.

DOI: 10.1158/2159-8290.22529738

Authors: Michel van Kruchten, Elisabeth G. de Vries, Andor W. Glaudemans, Meta C. van Lanschot, Martijn van Faassen, Ido P. Kema, Myles Brown, Carolien P. Schröder, Erik F. de Vries, Geke A. Hospers

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362531227

Cites:

Cited by:

Related to: 10